|
|
iCardiac: DSEC Signature Partner
 iCardiac Technologies is an innovative, research-driven service provider for pharmaceutical cardiac safety trials.
How iCardiac will Contribute to the DSEC community: iCardiac is focused on the development and qualification of advanced biomarkers for evaluation of arrhythmogenic potential of new and approved drugs. iCardiac translates advanced cardiac safety research into practical solutions for preclinical and clinical trials.
Capability Overview: iCardiac develops novel advanced ECG-based biomarkers, as well as improved methods for measuring standard ECG-based biomarkers in preclinical and clinical cardiac safety studies (Thorough QT studies).
Subject Matter Experts: Dr. Arthur J. Moss, Chairman of the Scientific Advisory Board, Professor of Medicine, University of Rochester Medical Center, Dr. Wojciech Zareba, Chief Medical Officer of iCardiac, Professor of Medicine, University of Rochester Medical Center, Dr. Jean-Philippe Couderc, Chief Technology Officer of iCardiac, Associate Professor, University of Rochester Medical Center, Dr. Anthony Fossa, Vice President, Cardiovascular Safety (formerly Research Fellow, Pfizer Global Pharmaceutical Research and Development)
Website: www.iCardiac.com
Current White Paper: iCardiac recently published a white paper entitled: Advanced ECG Markers. If you would like to download a copy, please fill in your e-mail address below: 
|